Richter Joel E
Dr Richter is a professor of medicine, the Hugh F. Culverhouse Chair for Esophagology, director of the Division of Digestive Diseases and Nutrition, and director of the Joy McCann Culverhouse Center for Swallowing Disorders at the University of South Florida Morsani College of Medicine in Tampa, Florida.
Gastroenterol Hepatol (N Y). 2014 Sep;10(9):547-55.
Suspected reflux symptoms that are refractory to proton pump inhibitors (PPIs) are rapidly becoming the most common presentation of gastroesophageal reflux disease (GERD) in patients seen in gastroenterology clinics. These patients are a heterogeneous group, differing in symptom frequency and severity, PPI dosing regimens, and responses to therapy (from partial to absent). Before testing, the physician needs to question the patient carefully about PPI compliance and the timing of drug intake in relation to meals. Switching PPIs or doubling the dose is the next step, but only 20% to 25% of the group refractory to PPIs will respond. The first diagnostic test should be upper gastrointestinal endoscopy. In more than 90% of cases, the results will be normal, but persistent esophagitis may suggest pill esophagitis, eosinophilic esophagitis, or rarer diseases, such as lichen planus, Zollinger-Ellison syndrome, or genotype variants of PPI metabolism. If the endoscopy results are normal, esophageal manometry and especially reflux testing should follow. Whether patients should be tested on or off PPI therapy is controversial. Most physicians prefer to test patients off PPIs to identify whether abnormal acid reflux is even present; if it is not, PPIs can be stopped and other diagnoses sought. Testing patients on PPI therapy allows nonacid reflux to be identified, but more than 50% of patients have a normal test result, leaving the clinician with a conundrum-whether to stop PPIs or continue them because the GERD is being treated adequately. Alternative diagnoses in patients with refractory GERD and normal reflux testing include achalasia, eosinophilic esophagitis, gastroparesis, rumination, and aerophagia. However, more than 50% will be given the diagnosis of functional heartburn, a visceral hypersensitivity syndrome. Treating patients with PPI-refractory GERD-like symptoms can be difficult and frustrating. Any of the following may help: a histamine-2 receptor antagonist at night, baclofen to decrease transient lower esophageal sphincter relaxations, pain modulators, acupuncture, or hypnotherapy. At this time, antireflux surgery should be limited to patients with abnormal acid reflux defined by pH testing and a good correlation of symptoms with acid reflux.
质子泵抑制剂(PPI)治疗无效的疑似反流症状正迅速成为胃肠病诊所中胃食管反流病(GERD)患者最常见的表现形式。这些患者是一个异质性群体,在症状频率和严重程度、PPI给药方案以及对治疗的反应(从部分反应到无反应)方面存在差异。在进行检测之前,医生需要仔细询问患者关于PPI的依从性以及药物摄入与进餐时间的关系。下一步是更换PPI或加倍剂量,但在对PPI治疗无效的患者群体中,只有20%至25%会有反应。首要的诊断检查应该是上消化道内镜检查。在超过90%的病例中,结果将是正常的,但持续性食管炎可能提示药物性食管炎、嗜酸性粒细胞性食管炎或更罕见的疾病,如扁平苔藓、卓-艾综合征或PPI代谢的基因变异。如果内镜检查结果正常,应接着进行食管测压,尤其是反流检测。患者是否应在PPI治疗期间或停药后进行检测存在争议。大多数医生倾向于在患者停用PPI后进行检测,以确定是否存在异常酸反流;如果不存在,则可以停用PPI并寻找其他诊断。在PPI治疗期间对患者进行检测可以识别非酸反流,但超过50%的患者检测结果正常,这让临床医生陷入两难境地——是停用PPI还是继续使用,因为GERD正在得到充分治疗。GERD难治且反流检测正常的患者的其他诊断包括贲门失弛缓症、嗜酸性粒细胞性食管炎、胃轻瘫、反刍和吞气症。然而,超过50%的患者将被诊断为功能性烧心,这是一种内脏高敏综合征。治疗有PPI难治性GERD样症状的患者可能既困难又令人沮丧。以下任何一种方法可能会有所帮助:夜间使用组胺-2受体拮抗剂、巴氯芬以减少食管下括约肌的短暂松弛、疼痛调节剂、针灸或催眠疗法。此时,抗反流手术应仅限于经pH检测确定存在异常酸反流且症状与酸反流有良好相关性的患者。